SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company is headquartered in Boulder, Colorado and currently employs 451 full-time employees. The company went IPO on 2021-02-23. The firm has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. The company develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The company offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.

Industry: Services-Commercial Physical & Biological Research Peers: Adaptive Biotechnologies Corp Akoya Biosciences, Inc. Neogenomics Inc Inotiv Inc Bionano Genomics Inc MaxCyte Inc Pacific Biosciences of California Inc NS Wind Down Co., Inc. Seer, Inc. Thermo Fisher Scientific Inc